Login Register Cart 0
Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Impact of Age and Gender Disparity on CD4+ Cell Counts to Control Disease Progression Using Specific HAART in HIV-1 Positive Patients: A Case-Control Study

Author(s): Aakansha Singh, Manoj Kumar, Ashok K. Singh and Neeraj Verma*

Volume 17, Issue 3, 2022

Published on: 08 September, 2022

Page: [195 - 207] Pages: 13

DOI: 10.2174/1574887117666220817123002

Price: $65

Abstract

Background: Highly Active Antiretroviral Therapy (HAART) is composed of several drugs in the antiretroviral class to better treat human immunodeficiency virus type 1 (HIV-1) patients. The estimation of CD4+ T cell counts and HIV-1 viral load in plasma is required to evaluate the treatment success of a specific HAART.

Methodology: The study included the effects of NRTIs (nucleoside reverse transcriptase inhibitors) and novel protease inhibitors (HAART) on normal control subjects and HIV-1 positive subjects from SGPGIMS, Lucknow, with different age groups and genders. Furthermore, the study was conducted by the estimation of HIV through ELISA, measurement of absolute CD4+ cell count, and the measurement of viral load through qRT-PCR. Furthermore, NRTIs (Retrovir and Epivir) were administered orally one tablet daily in the morning followed by newly FDA-approved protease inhibitors (fosamprenavir and darunavir) orally in the evening at the same dose. Furthermore, CD4+T cell counts and HIV-1 viral load were investigated and correlated in patients with different genders and age groups.

Results: Administration of NRTIs and novel protease inhibitors (HAART) in HIV patients had a significant effect on the CD4+ cell count in various age intervals among males and females.

The mean comparison of viral load distribution based on gender in CD4 +ve patients in the case group exhibited a viral load higher in females compared to males, indicating a statistically significant difference between males and females (p<0.05). A notable association between virological and immunological parameters was observed with a reciprocal relationship between viral load and CD4 cell count in CD4 +ve patients, demonstrating multiple correlation coefficients with an R-value of 0.853.

Conclusion: The administration of specific HAART (NRTIs and novel protease inhibitors) in HIV patients had a notable improvement in the CD4+ cell count and viral load with significant age and gender disparity.

Keywords: CD4, CD8, HIV, ELISA, qRT-PCR, HAART (NRTIs and novel protease inhibitors)

« Previous Next »
Graphical Abstract

[1]
Utama S, Patriawan P, Dewi A. Correlation of CD4/CD8 ratio with carotid intima-media layer thickness in HIV/AIDS patients at Sanglah General Hospital, Bali, Indonesia. Open Access Maced J Med Sci 2019; 7(11): 1803-7.
[http://dx.doi.org/10.3889/oamjms.2019.479] [PMID: 31316662]
[2]
Amadori A, Zamarchi R, Chieco-Bianchi L. CD4: CD8 ratio and HIV infection: The "tap-and-drain’ hypothesis. Immunol Today 1996; 17(9): 414-7.
[http://dx.doi.org/10.1016/0167-5699(96)10049-9] [PMID: 8854558]
[3]
Petoumenos K, Choi JY, Hoy J, et al. CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy. Antivir Ther 2017; 22(8): 659-68.
[http://dx.doi.org/10.3851/IMP3155] [PMID: 28291735]
[4]
Catalfamo M, Wilhelm C, Tcheung L, et al. CD4 and CD8 T cell immune activation during chronic HIV infection: Roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol 2011; 186(4): 2106-16.
[http://dx.doi.org/10.4049/jimmunol.1002000] [PMID: 21257970]
[5]
Mussini C, Lorenzini P, Cozzi-Lepri A, et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study. Lancet HIV 2015; 2(3): e98-e106.
[http://dx.doi.org/10.1016/S2352-3018(15)00006-5] [PMID: 26424550]
[6]
Masiá M, Padilla S, Barber X, et al. Comparative impact of suppressive antiretroviral regimens on the CD4/CD8 T-cell ratio: A cohort study. Medicine (Baltimore) 2016; 95(11): e3108.
[http://dx.doi.org/10.1097/MD.0000000000003108] [PMID: 26986155]
[7]
Tinago W, Coghlan E, Macken A, et al. Clinical, immunological and treatment-related factors associated with normalised CD4+/CD8+ T-cell ratio: Effect of naïve and memory T-cell subsets. PLoS One 2014; 9(5): e97011.
[http://dx.doi.org/10.1371/journal.pone.0097011] [PMID: 24816636]
[8]
Goicoechea M, Smith DM, Liu L, et al. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: Association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 2006; 194(1): 29-37.
[http://dx.doi.org/10.1086/504718] [PMID: 16741879]
[9]
Gibert CL. Treatment guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents: An update. Fed Pract 2016; 33(3): 31S-6S.
[PMID: 30766213]
[10]
Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373(9): 795-807.
[http://dx.doi.org/10.1056/NEJMoa1506816] [PMID: 26192873]
[11]
World Health Organization. WHO Technical Brief Viral Load DRAFT _June 2010 docx WHO 2010. Available from: https://www.who.int/hiv/topics/treatment/tech brief_20100601_en.pdf
[12]
Monsalvo M, Vallejo A, Fontecha M, Vivancos MJ, Vizcarra P, Casado JL. CD4/CD8 ratio improvement in HIV-1-infected patients receiving dual antiretroviral treatment. Int J STD AIDS 2019; 30(7): 656-62.
[http://dx.doi.org/10.1177/0956462419834129] [PMID: 30961467]
[13]
Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection: Undetectable equals untransmittable. JAMA 2019; 321(5): 451-2.
[http://dx.doi.org/10.1001/jama.2018.21167] [PMID: 30629090]
[14]
Koenig SP, Bang H, Severe P, et al. Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti. PLoS Med 2011; 8(9): e1001095.
[http://dx.doi.org/10.1371/journal.pmed.1001095] [PMID: 21949643]
[15]
Kim KH, Yi J, Lee SH. The CD4 slope can be a predictor of immunologic recovery in advanced HIV patients: A case-control study. Korean J Intern Med (Korean Assoc Intern Med) 2015; 30(5): 705-13.
[http://dx.doi.org/10.3904/kjim.2015.30.5.705] [PMID: 26354065]
[16]
El-Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355(22): 2283-96.
[http://dx.doi.org/10.1056/NEJMoa062360] [PMID: 17135583]
[17]
Bystryak S, Acharya C. Detection of HIV-1 p24 antigen in patients with varying degrees of viremia using an ELISA with a photochemical signal amplification system. Clin Chim Acta 2016; 456: 128-36.
[http://dx.doi.org/10.1016/j.cca.2016.02.022] [PMID: 26940950]
[18]
Macchi B, Frezza C, Marino-Merlo F, et al. Appraisal of a simple and effective RT-qPCR assay for evaluating the reverse transcriptase activity in blood samples from HIV-1 patients. Pathogens 2020; 9(12): 1047.
[http://dx.doi.org/10.3390/pathogens9121047] [PMID: 33322208]
[19]
Kumar M, Kumar R, Mahdi AA, et al. CD4 count pattern and demographic distribution in HIV positive patients in northern part of India. J Fam Med 2019; 6(6): 1183.
[20]
Yar’zever IS, Abubakar U, Toriola AL, et al. Effects of 12 weeks cycle exercise programme on CD4 count and viral load in HIV sero-positive patients in Kano, Nigeria. Global Sci Res J 2013; 1(1): 22-8.
[21]
Abrams D, Lévy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361(16): 1548-59.
[http://dx.doi.org/10.1056/NEJMoa0903175] [PMID: 19828532]
[22]
Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335(18): 1350-6.
[http://dx.doi.org/10.1056/NEJM199610313351803] [PMID: 8857018]
[23]
Stringer WW. HIV and aerobic exercise. Current recommendations. Sports Med 1999; 28(6): 389-95.
[http://dx.doi.org/10.2165/00007256-199928060-00002] [PMID: 10623982]
[24]
Gallagher KM, Sullivan PS, Lansky A, Onorato IM. Behavioral surveillance among people at risk for HIV infection in the U.S.: The national HIV behavioral surveillance system. Public Health Rep 2007; 122(1): 32-8.
[http://dx.doi.org/10.1177/00333549071220S106] [PMID: 17354525]
[25]
Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One 2014; 9(5): e97596.
[http://dx.doi.org/10.1371/journal.pone.0097596] [PMID: 24840662]
[26]
Halperin DT. Heterosexual anal intercourse: Prevalence, cultural factors, and HIV infection and other health risks, Part I. AIDS Patient Care STDS 1999; 13(12): 717-30.
[http://dx.doi.org/10.1089/apc.1999.13.717] [PMID: 10743535]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy